Holen Sie sich die Stockscreener-App
16.38
2.44%
0.39
Handel nachbörslich:
16.38
Schlusskurs vom Vortag:
$15.99
Offen:
$16.21
24-Stunden-Volumen:
4.00M
Relative Volume:
1.76
Marktkapitalisierung:
$1.40B
Einnahmen:
$139.71M
Nettoeinkommen (Verlust:
$-209.36M
KGV:
-5.5338
EPS:
-2.96
Netto-Cashflow:
$-160.60M
1W Leistung:
+9.79%
1M Leistung:
+19.82%
6M Leistung:
-19.39%
1J Leistung:
-26.32%
1-Tages-Spanne:
$16.12
$16.95
1-Wochen-Bereich:
$14.53
$16.95
52-Wochen-Spanne:
$12.06
$25.34
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Firmenname
Syndax Pharmaceuticals Inc
Sektor
Branche
Telefon
781-419-1400
Adresse
35 GATEHOUSE DRIVE, WALTHAM, MA
Vergleichen Sie SNDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
16.38 | 1.40B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-10-25 | Eingeleitet | BofA Securities | Buy |
| 2023-10-11 | Eingeleitet | Goldman | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-11 | Eingeleitet | Guggenheim | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2023-01-03 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-28 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-04-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-15 | Eingeleitet | Goldman | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-25 | Eingeleitet | Citigroup | Buy |
| 2021-02-18 | Eingeleitet | B. Riley Securities | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-05-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-01-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Eingeleitet | FBR & Co. | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-10-07 | Eingeleitet | Guggenheim | Buy |
| 2016-03-28 | Eingeleitet | Citigroup | Buy |
| 2016-03-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-03-28 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.7%Here's What Happened - MarketBeat
Should investors be concerned about SNDX’s high price-to-sales ratio? - US Post News
Syndax Pharmaceuticals (SNDX) Projected to Post Earnings on Tuesday - MarketBeat
Here's Why We're Watching Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation - Yahoo Finance
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
When (SNDX) Moves Investors should Listen - Stock Traders Daily
Syndax Pharmaceuticals' SWOT analysis: stock poised for growth with FDA approvals - Investing.com
Insider Selling: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Insider Sells 4,618 Shares of Stock - MarketBeat
Insider Selling: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Sells 3,777 Shares of Stock - MarketBeat
Michael A. Metzger Sells 13,288 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Syndax pharmaceuticals CFO Keith Goldan sells $58,558 in stock - MSN
Don't Ignore The Insider Selling In Syndax Pharmaceuticals - Simply Wall St
abrdn plc Takes Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax pharmaceuticals CFO sells $58,558 in stock - MSN
Syndax Pharmaceuticals CEO sells $206,017 in shares - MSN
Syndax pharmaceuticals CFO Keith Goldan sells $58,558 in stock By Investing.com - Investing.com Australia
Syndax pharmaceuticals CFO sells $58,558 in stock By Investing.com - Investing.com Nigeria
Syndax Pharmaceuticals CEO sells $206,017 in shares By Investing.com - Investing.com South Africa
Syndax Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
Is Syndax Pharmaceuticals Inc (SNDX) positioned for future growth? - SETE News
2 ‘Strong Buy’ Growth Stocks Poised For 141% To 193% Gains, According To Wall Street - Barchart
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap UpShould You Buy? - MarketBeat
Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm - GlobeNewswire Inc.
Learn to Evaluate (SNDX) using the Charts - Stock Traders Daily
Syndax Pharmaceuticals Inc [SNDX] stock for 25,037 USD was acquired by Goldan Keith A. - Knox Daily
Syndax Pharmaceuticals Inc (SNDX) deserves deeper analysis - US Post News
Kura Oncology falls despite trial success; rival Syndax gains - Seeking Alpha
Can Syndax Pharmaceuticals Inc Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
Syndax Expands Team: Strategic Stock Options Grant Signals Major Growth Phase - StockTitan
Ready to Jump After Recent Trade: Syndax Pharmaceuticals Inc (SNDX) - SETE News
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance
Syndax Leadership Reveals Growth Strategy at Elite Healthcare Investment Forums - StockTitan
Syndax Announces Participation in February Investor Conferences - Yahoo Finance
(SNDX) Investment Analysis and Advice - Stock Traders Daily
Incyte and Syndax to scale Niktimvo production after FDA approval - BioProcess Insider
Finanzdaten der Syndax Pharmaceuticals Inc-Aktie (SNDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):